Innoviva, Inc. (INVA) — closed signal from December 23, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 23, 2026.
Predicted vs. what happened
What happened
Reached its target in 65 days.
The thesis — published December 23, 2025
INVA's recent FDA approval for a new oral gonorrhea drug and an analyst raising the price target to $46 put the company back in the spotlight ahead of a planned H2 2026 launch. The stock has fallen a lot recently, which can lead to a fast bounce as traders buy discounted shares. Small-company risks mean keep positions small.
Primary drivers
- FDA approval gives a clear, time-limited reason for buyers to reprice the stock
- Higher analyst price target attracts extra interest from investors
- The stock's recent heavy selling can spark a sharp rebound as buyers step in
- Royalty and asset structure gives the company flexibility around launch timing
How it played out
INVA: target reached in 65 days
Lyra published INVA at $19.98 on 2025-12-23 with a short-term thesis for 25% growth. The thesis pointed to FDA approval for a new oral gonorrhea drug, a higher analyst price target of $46, recent heavy selling, and a royalty and asset structure that gave the company flexibility around launch timing.
Inside the window, the stock reached a peak of $25.15 on 2026-02-26, above the $24.98 target. It got there in 65 days. The peak gain was 25.9%. By 2026-03-23, INVA ended at $21.91. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.